Years increasing dividends5.0
#1 of 10054 reported increase years. Years / 10, capped at 5 points.
Nanalyze Dividend
ABBV AbbVie Inc.
Biopharmaceutical cash flows provide a healthcare dividend comparison. Patent expirations, pipeline execution and debt are central risks.
Q-score estimate13.8#63 of 100 assessed stocks
Years increasing dividends and market capitalization contribute the most. Payout ratio is the largest constraint. Independent estimate from dated inputs, not a publisher Q-score.
Hypothetical investment
Growth of $10,000
Dividends reinvested · no additional contributions
ABBV would be worth$29,8055-year growth · as of Sep 18, 2026
S&P 500 (SPY)$18,763Same $10,000 · same dates
Total gain / loss+$19,805+198.1% total return
ABBVS&P 500 (SPY)
Sep 20, 2021 · $10,000 investedSep 18, 2026
Based on adjusted market prices through the latest available completed session, before personal taxes and trading costs.
Checking the latest completed session…
Market performance
Total return
Price movement plus reinvested distributions, compared with SPY.
+198.1% over 5 years
1 YEAR TOTAL RETURN+22.6%#27 return rank · 100 peers
Price84% of return+18.9%
Dividend16% of return+3.7%
5 YEARS TOTAL RETURN+198.1%+24.4% / yr annualized#7 return rank · 99 peers
Price75% of return+148.1%
Dividend25% of return+50.0%
Dividend includes all distributions and reinvestment.
Sep 20, 2021Sep 18, 2026
Total return+198.05%
S&P 500 (SPY)+87.63%
Annualized return+24.44%
Largest drawdown-21.92%
Transparent factor breakdown
Official framework Why the Q-score estimate is 13.8
Each rank compares this stock with the 100 assessed stocks in the Nanalyze collection.
Market capitalization5.0
#1 of 100$434.07 billion. 2 × log10(market cap in USD billions), limited to 0–5 points.
Dividend yield2.6
#34 of 1002.82%. 2 × (yield % − 1.5), limited to −2–5 points.
Payout ratio-2.0
#92 of 100325.98%. (90 − payout %) / 15, limited to −2–5 points. Zero or negative payout receives −2 rather than a false coverage reward.
International sales-1.0
#57 of 10023.90% source geographic share. At most 25%: −1 point; above 25% through 50%: 2.5; above 50%: 5. A verified upper bound is usable only when entirely within the lowest band.
5-year dividend growth0.3
#54 of 1005.88%. (5-year growth % − 5) / 3, limited to −2–5 points.
10-year dividend growth3.9
#13 of 10011.74%. (10-year growth % − 4) / 2, limited to −2–5 points.
Independent estimate · assessed October 10, 2026. All 100 research stocks use the same rules. Each component is rounded to one decimal before summing; equal totals share a rank. These scores are not Nanalyze’s published Q-scores. Full method
Supplied Quantigence ALL calculator; imported 2026-09-23; effective date unstated. Quantigence Q-Score Calculator - ALL.csv, row 28; source symbol ABBV. Supplied publisher total: 16.6 (separate scale; not used in this ranking).
Inputs are a supplied calculator snapshot, not live values; its effective date is unstated. Geography and payout definitions are retained as supplied.
Why it is in this section
Biopharmaceutical cash flows provide a healthcare dividend comparison.
What to investigate
Patent expirations, pipeline execution and debt are central risks.
Independent selection; creator ownership or endorsement has not been verified. NOBL screens for a 25-year dividend-increase record; index treatment can include predecessor history. Q-score not assessed.